OTCMKTS:SNPHY Santen Pharmaceutical (SNPHY) Stock Price, News & Analysis $12.56 -0.03 (-0.24%) As of 02:29 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and TrendsShort Interest About Santen Pharmaceutical Stock (OTCMKTS:SNPHY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Santen Pharmaceutical alerts:Sign Up Key Stats Today's Range$12.56▼$12.7150-Day Range$10.23▼$12.8152-Week Range$9.60▼$13.93Volume1,129 shsAverage Volume7,946 shsMarket Capitalization$4.05 billionP/E RatioN/ADividend Yield1.11%Price TargetN/AConsensus RatingHold Company Overview Santen Pharmaceutical is a Japan-based pharmaceutical company focused on eye care. Founded in 1890, it researches, develops, manufactures and markets treatments for ophthalmic conditions. Its products include prescription medicines for conditions such as glaucoma, dry eye and retinal diseases, as well as over-the-counter eye drops and other eye-care products. The company also offers products for eye surgery and related medical needs. Headquartered in Osaka, Santen serves patients and healthcare professionals in Japan and international markets, including other parts of Asia, Europe and the Middle East and Africa.AI Generated. May Contain Errors. Read More Santen Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreSNPHY MarketRank™: 1.31033542405 of 5 starsSanten Pharmaceutical scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingSanten Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSanten Pharmaceutical has received no research coverage in the past 90 days.Read more about Santen Pharmaceutical's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth18.75% Earnings GrowthEarnings for Santen Pharmaceutical are expected to grow by 18.75% in the coming year, from $0.80 to $0.95 per share. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Santen Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverSanten Pharmaceutical has a short interest ratio ("days to cover") of 1.21, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Santen Pharmaceutical has recently increased by 1,319.00%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldSanten Pharmaceutical pays a meaningful dividend of 1.11%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSanten Pharmaceutical does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Santen Pharmaceutical will have a dividend payout ratio of 14.74% next year. This indicates that Santen Pharmaceutical will be able to sustain or increase its dividend.Read more about Santen Pharmaceutical's dividend. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Santen Pharmaceutical this week, compared to 0 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Santen Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InstitutionsSanten Pharmaceutical has minimal institutional ownership at this time.Read more about Santen Pharmaceutical's insider trading history. Receive SNPHY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santen Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNPHY Stock News HeadlinesSanten Pharmaceutical Co ADR (SNPHY)November 13, 2026 | investing.comSanten Pharmaceutical Co. - Depositary receipt price target increased by 11.75% to $15.41October 23, 2026 | msn.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 19 at 1:00 AM | Profits Run (Ad)Santen Pharmaceutical Co Stock Price HistorySeptember 3, 2026 | investing.comSanten Pharmaceutical Co., Ltd. GAAP EPS of ¥22.30, revenue of ¥68.9BAugust 6, 2026 | seekingalpha.comSanten boosts profits in Q1 and maintains upbeat full-year outlookAugust 6, 2026 | tipranks.comSanten Pharmaceutical Co Ltd ADR SNPHYMay 14, 2026 | morningstar.comMSanten Pharmaceutical Co., - Depositary Receipt (SNPHY) Price Target Decreased by 10.74% to 13.32November 9, 2025 | msn.comSee More Headlines SNPHY Stock Analysis - Frequently Asked Questions How have SNPHY shares performed this year? Santen Pharmaceutical's stock was trading at $10.30 on January 1st, 2026. Since then, SNPHY stock has increased by 21.9% and is now trading at $12.56. How do I buy shares of Santen Pharmaceutical? Shares of SNPHY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/19/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:SNPHY CIK1501108 Webwww.santen.com Phone(167) 664-8621FaxN/AEmployees3,968Year Founded1890Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares322,310,000Free FloatN/AMarket Cap$4.05 billion OptionableNot Optionable BetaN/A Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:SNPHY) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersI wasn't planning on sharing this yet, but here it isMarkham Trading's complete Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 f...TradeWins | SponsoredChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santen Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Santen Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.